Search - tctmd.com

Displaying 21 - 40 of 204

Sort: Relevancy | Date

News Conference News TCT 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Yael L. Maxwell

September 27, 2022

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

Presentation Cardiovascular Interventions 2020

Structure Impacts Function: Improved Outcomes with the Thin Strut Orsiro Stent

Presenter: James Hermiller

November 13, 2020

Presentation TCT 2020

TCT 286: Long-Term Outcomes Following Drug-Eluting Balloon Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis: Multicenter Propensity Score-Matched Analysis (DEB-Dragon Registry)

Presenter: Wojciech Wanha

October 14, 2020

Presentation TCT 2020

TCT 271: The MeRes-1 Extend Trial: Two-Year Clinical and Six-Month Imaging Outcomes of Thin Strut Sirolimus-Eluting BRS in Patients With De Novo Coronary Artery Lesions

Presenter: Alexandre Abizaid

October 14, 2020

Presentation TCT 2020

TCT 269: A First-in-Human Study of the Second-Generation, Thin-Strut, Everolimus-Eluting Bioresorbable Scaffold: Final IVUS and OCT Results From the FAST Clinical Trial

Presenter: Takeshi Nishi

October 14, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Advertisement

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Good Long-term Results With FANTOM BVS, but More Data Needed

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Structure Impacts Function: Improved Outcomes with the Thin Strut Orsiro Stent

TCT 286: Long-Term Outcomes Following Drug-Eluting Balloon Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis: Multicenter Propensity Score-Matched Analysis (DEB-Dragon Registry)

TCT 271: The MeRes-1 Extend Trial: Two-Year Clinical and Six-Month Imaging Outcomes of Thin Strut Sirolimus-Eluting BRS in Patients With De Novo Coronary Artery Lesions

TCT 269: A First-in-Human Study of the Second-Generation, Thin-Strut, Everolimus-Eluting Bioresorbable Scaffold: Final IVUS and OCT Results From the FAST Clinical Trial

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content